Acquisitions and Divestiture (Tables)

6 Months Ended

Jun. 30, 2019

Schedule of the amounts recognized for assets acquired and liabilities assumed as of the acquisition date

The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:



Estimated Fair Value at February 15, 2019
Acquired in-process research and development	$	4,670.0
Definite-lived intangibles ⁽¹⁾	960.0
Deferred income taxes	(1,134.3		)
Other assets and liabilities - net	(31.4		)
Total identifiable net assets	4,464.3
Goodwill ⁽²⁾	2,453.4
Total consideration transferred - net of cash acquired	$	6,917.7

⁽¹⁾Contract-based intangibles, which are being amortized to cost of sales on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of approximately 12 years from the acquisition date.

⁽²⁾The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Loxo and is not deductible for tax purposes.

Schedule of asset acquisition

The following table summarizes our asset acquisitions during the six months ended June 30, 2019 and June 30, 2018.



Counterparty	Compound(s) or Therapy	Acquisition Month	Phase of Development ⁽¹⁾	Acquired IPR&D Expense
AC Immune SA	Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease and other neurodegenerative diseases	January 2019	Pre-clinical	$	96.9
ImmuNext, Inc.	Novel immunometabolism target	March 2019	Pre-clinical	40.0
Avidity Biosciences, Inc.	Potential new medicines in immunology and other select indications	April 2019	Pre-clinical	25.0

Sigilon Therapeutics	Encapsulated cell therapies for the potential treatment of type 1 diabetes	April 2018	Pre-clinical	66.9
AurKa Pharma, Inc.	AK-01, an Aurora kinase A inhibitor	June 2018	Phase I	81.8
ARMO Biosciences, Inc.	Cancer therapy - pegilodecakin	June 2018	Phase III	1,475.8

⁽¹⁾The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.